Organ Transplant Immunosuppressive Markets

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Waiting List Candidates (Active and Inactive Combined), in U.S., 2004-2005
• Table 1-2: Current Organ Waiting List, Number of
• Transplant Procedures and Number of Donor Organs Recovered, in U.S., 2007
• Table 1-3: Growth in Number of Transplanted and Recovered Organs, in U.S., 2004-2005
• Table 1-4: Unadjusted One-and Five-Year Patient Survival by Organ, in the U.S.
• Table 1-5: Number of Deceased Donor's Organs Used for Transplant, by Organ, as Reported by Eurotransplant, from 2002-2006
• Table 1-6: Current Waiting List for Solid Organs, as Reported by Eight European Countries, as of September 2007
• Table 1-7: Chronological Development of Transplant Immunosuppressive Therapies
• Table 1-8: Global Transplant Immunosuppressant Market, 2002-2012
• Figure 1-1: Market Share of Immunosuppressive Categories, 2006
• Figure 1-2: Immunosuppressant Sales by Geographical Region, 2006
• Figure 1-3: Immunosuppressant Market, by Organ Transplanted, 2006 (Kidney, Kidney/Pancreas, Liver, Lung, Heart)
• CHAPTER TWO: SOLID ORGAN TRANSPLANTATION
• Table 2-1: Landmarks in Organ Transplantation in the United States and Canada
• Table 2-2: Estimated US Average First-Year Billed Charges per Transplant, 2005
• Table 2-3: Waiting List Candidates (Active and Inactive Combined), in U.S., 2004-2005
• Table 2-4: Current Organ Waiting List, Number of Transplant Procedures
• Performed and Number of Donor Organs Recovered, in U.S., 2007
• Table 2-5: Growth in Number of Transplanted and Recovered Organs, in U.S., 2004-2005
• Table 2-6: Unadjusted One-and Five-Year Patient Survival by Organ, in U.S.
• Table 2-7: Unadjusted One-and Five-Year Graft Survival by Organ, in U.S.
• Table 2-8: Number of Deceased Donor's Organs Used for Transplant, by Organ, as Reported by Eurotransplant, from 2002-2006
• Table 2-9: Number of Deceased Donor's Organs Used for Transplant, by Organ and Country, as Reported by Eurotransplant, 2002-2006
• Table 2-10: Summary of Donor and Transplant Activity in the United Kingdom and the Republic of Ireland for 2005-2006
• Table 2-11: Current Waiting List for Solid Organs, as Reported by Eight European Countries, as of September 2007
• Table 2-12: Types of Transplant Rejection, by Organ
• CHAPTER THREE: TRANSPLANT IMMUNOSUPPRESSIVE THERAPIES
• Table 3-1: Chronological Development of Transplant Immunosuppressive Therapies
• Table 3-2: Most Commonly Prescribed Transplant Immunosuppressant Agents
• Table 3-3: Steroid Avoidance Rate at Discharge, 1996 to 2005 Recipients of Deceased Donor Kidneys
• Table 3-4: Steroid Avoidance Rate at Discharge, 1996-2005 Recipients of Deceased Donor Livers
• Table 3-5: Steroid Avoidance Rate at Discharge, 1996 to 2005 Recipients of Heart Transplants
• Table 3-7: Estimated Monthly Cost of Immunuosuppressant Drugs
• CHAPTER FOUR: MARKET ANALYSIS
• Figure 4-1: Comparative Calcineurin Inhibitor Use for Immunosuppressive Prior to Discharge, by Organ, 2003
• Figure 4-2: Comparative Use of Maintenance Antimetabolite and Sirolimus Immunosuppression Prior to Discharge, by Organ, 2003
• Figure 4-3: Immunosuppression Agents Used for Induction in Kidney Transplantation, 1996-2005
• Table 4-1: Immunosuppression Use for Kidney Transplant Maintenance Prior to Discharge, 1996 to 2005
• Table 4-2: Decrease in Acute Rejection Incidence Within a Year of Kidney Transplant, 1996-2003
• Table 4-3: Immunosuppression Use for PTA Maintenance Prior to Discharge, 1996 to 2005
• Table 4-4: Immunuosuppression Use: Liver Antirejection Treatment from Transplant to One Year Posttransplant, 1994-2003
• Table 4-5: Immunosupression Use for Maintenance Prior to Discharge for Intestine Transplants, 1995-2004
• Table 4-6: Immunosuppression Use for Induction in Lung Transplantation, 1996-2005
• Table 4-7: Immunosuppression Use of Maintenance Prior to Discharge for Lung Transplant Recipients, 1996-2005
• Table 4-8: Immunosuppression Use for Antirejection of Lung Transplant up to One Year Following Transplantation, 1995-2004
• Table 4-9: Immunosuppression Use for Induction for Recipients of Heart Transplants, 1996-2005
• Table 4-10: Immunosuppression Usage Rates from Discharge to One Year Post-Transplantation for Heart Recipients, 1994 & 1995
• Table 4-11: Immunusuppression use for Induction in Heart-Lung Transplantations, 1996-2005
• Table 4-12: Most Commonly Used Immunosuppressants, by Organ (Kidney, Kidney/Pancreas, Lung, Heart, Liver)
• Table 4-13: Global Transplant Immunosuppressant Market, 2002-2012
• Figure 4-5: Market Share of Immunosuppressive Categories, 2006 (Calcineurin Inhibitors, Corticosteroids, Polyclonal Antibodies, Monoclonal Antibodies, TOR Inhibitors, Antiproliferative Agents)
• Figure 4-6: Immunosuppressant Sales by Geographical Region, 2006
• Figure 4-7: Value of Immunosuppressant Market, by Transplanted Organ, 2006 (Kidney, Kidney/Pancreas, Lung, Heart, Liver)
• Figure 4-8: Immunosuppressant Market, by Transplanted Organ, by Percent (Kidney, Kidney/Pancreas, Lung, Heart, Liver)
• Figure 4-9: Top-Selling Transplant Immunosuppressants, by Brand Name, 2006
• Table 4-14: Transplant Immunosuppressant Market Share, by Manufacturer, 2006 ($billions)